Apremilast
BRAND NAME: none yet
GENERIC NAME: apremilast
EXPERIMENTAL/INTERNAL COMPANY NAME: CC-10004 |
|
| DRUG USE (P OR PsA) | METHOD OF DELIVERY | DEVELOPING COMPANY/COMPANIES |
| Moderate to severe psoriasis, psoriatic arthritis | Pill | Celgene |
Description and Comments
Apremilast enjoys considerable buzz, for a variety of reasons. It is made by a highly-regarded company, Celgene. It is taken as a pill, which even at twice a day is considered a pretty easy regimen. And Phase Two results give people hope it may prove both effective and safe.
But don't run to your dermatologist just yet. Barron's believes apremilast might hit the US market in 2015...if it pans out in Phase Three trials, which are expected to begin in the second half of 2010.
About one-third of patients achieved major improvement in separate Phase Two trials in psoriasis and psoriatic arthritis. The company will now decide which dosing regimens to test in Phase Three.
Apremilast is a pill with anti-inflammatory properties that lead some to think of it as a potential "biologic in a pill."
(Celgene has high hopes for apremilast and is already studying it in at least 10 other diseases and ailments.)
Other News and Links
Phase Two results in psoriasis.
Phase Two results in psoriatic arthritis.
